|
|
||||||||
ORIGINAL ARTICLE |
Department of Cardiothoracic Surgery John Radcliffe Hospital Oxford, UK
Ravi Pillai, FRCS Tel: +44 1865 220240 Fax: +44 1865 220244 Email: ravi.pillai{at}nds.ox.ac.uk, Department of Cardiothoracic Surgery, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
ABSTRACT
Stentless aortic bioprostheses have been successfully used for over a decade. The 3f bioprosthesis is a new equine pericardial stentless valve, unique in its tubular design, preserving the native aortic sinuses post-implant. Forty-six consecutive aortic valve replacements with the 3f bioprosthesis were performed between June 2003 and January 2005. The patients were prospectively assessed and echocardiography was performed at 6 months, 12 months, and annually thereafter. The median follow-up was 2.1 ± 0.9 years. There was one early and 4 late deaths; none were valve-related. The 2-year mean transvalvular gradient was 8.8 ± 3.8 mm Hg, the mean echocardiographic aortic regurgitation grade was 0.4 ± 0.7 (grade 1 being trivial). Echocardiographic sizing of the aortic annulus before surgery accurately predicted prosthesis size. The 3f bioprosthesis is easy to implant. Early clinical results are favorable, with hemodynamic profiles consistent with those of other stentless prostheses. Longer follow-up is required to confirm its durability.
Key Words: Aortic Valve Heart Valve Prosthesis Implantation
Asian Cardiovasc Thorac Ann 2010;
18:13-16
© 2010 by SAGE Publications
DOI: 10.1177/0218492309355489
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |